Liam F. Spurr, MD
@lfspurr
PGY-1 - IM @EndeavorHlth ➡️ @MDAndersonNews #RadOnc ☢️ | via @UChiPritzker @BroadInstitute @GWtweets | 🔬: interplay of radiotherapy & genomics | 🏳️🌈
ID: 1247148095458205696
http://scholar.google.com/citations?user=QFxO9FwAAAAJ&hl=en 06-04-2020 13:04:17
328 Tweet
515 Followers
577 Following
Thank you Grey's Anatomy for highlighting our COSINR trial at UChicagoCancerCenter University of Chicago Radiation Oncology for cytoreductive ablative radiotherapy and immunotherapy for first-line metastatic NSCLC.
🚀 Excited to share our latest research! We developed GRITIC, a novel method for timing genomic gains using bulk WGS data. Our findings reveal non-parsimonious evolution and increased chromosomal instability post-genome doubling in tumors. aacrjournals.org/cancerdiscover… #cancergenomics
Hot off the press in IJROBP - The Red Journal: the ARREST phase I trial of SABR in poly-metastatic disease, led by Glenn Bauman, MD & Tim Nguyen Average number of lesions = 16 Dose safely escalated to 30 Gy in 5 fractions. sciencedirect.com/science/articl… The phase II/III RCT ARREST2 is underway!
Congrats Ethan Ludmir MD and Chad Tang, MD! This MD Anderson Cancer Center P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in #PancreasCancer pts with oligometastatic dz treated with metastasis-directed therapy+sys tx vs. sys tx alone. #radonc #endcancer ascopubs.org/doi/10.1200/JC…
Just published in Annals of Oncology ESMO - Eur. Oncology our paper on intrapatient variation in PD-L1 and TMB in #NSCLC authors.elsevier.com/c/1jZPc3I2OQih… Jim Smithy Biagio Ricciuti, MD PhD João Alessi, MD Federica Pecci Mark Awad
Check out the new study from Sean Pitroda, M.D. and I, providing further validation for aneuploidy as a predictive and prognostic biomarker following immunotherapy in patients with non-small cell lung cancer! nature.com/articles/s4159…